– Dr. Guy Sauvageau, Chief Scientific Officer at ExCellThera will present on current indications and prospects of hematopoietic stem cell expansion at the EBMT 2024 Annual Meeting.
MONTREAL, March 27, 2024 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today that Dr. Guy Sauvageau, the company’s Chief Scientific Officer, will present on significant advances in hematopoietic stem cell (HSC) expansion during the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).
Presentation details:
Date & Time: April 17, 2024 at 8:30 a.m. UK Time (4:30 a.m. ET) Title: Hematopoietic stem cell expansion: current indications and future prospects Session: E08: Improving transplant outcomes Presenter: Guy Sauvageau, MD, PhD, University of Montreal, Montreal, Canada Location: Hall 3 North, Scottish Event Campus, Glasgow, UK
Over the years, Dr. Guy Sauvageau’s group at the Institute of Research in Immunology and Cancer (IRIC) in Montreal identified major determinants of HSC self-renewal that are central to this process. More recently, and in close collaboration with medicinal chemists at IRIC, the group developed a small molecule called UM171 that involves a new E3 ligase complex which appears central to the epigenetic control of HSC expansion both in vitro and in vivo. This new molecule has been used to expand cord blood stem cells prior to their transplantation leading to impressive clinical results that appear to outperform standard of care HSC transplants in patients with blood cancers. The potential of UM171 and its unique mechanism of action is being further investigated to make human HSC transplants, including gene therapy/editing, safer and more widely available.
About UM171 Cell Therapy
UM171 Cell Therapy developed by ExCellthera has been evaluated in 120 patients to treat hematologic malignancies in clinical trials in the United States, Europe and Canada. UM171 Cell Therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designation from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. UM171 Cell Therapy has successfully completed Phase 2 trials in high and very high-risk acute leukemias and myelodysplasias, and a Phase 3 trial is now planned in 2024.
Patients with high and very high-risk acute leukemias and myelodysplasias, including patients with refractory or active disease, patients requiring a second transplant, and patients with TP53 mutations or other genetic abnormalities, have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care.
The use of UM171 Cell Therapy in other patient populations, including patients with multiple myeloma, pediatric patients with high-risk leukemia and patients with non-malignant hematological diseases, is also being explored.
UM171 Cell Therapy is an investigational cell therapy, and its safety and efficacy have not been established by the FDA, EMA, Health Canada or any other health authority.
About ExCellThera and UM171 Technology
ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding HSCs from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn.
